Remove Biopharma Remove Competition Remove Physicians Remove Specialization
article thumbnail

Three Sales Compensation Pitfalls to Avoid for a Rare Disease Product Launch

The Marketing Advantage

Lack of Data and/or Proxies There is typically little to no competitive data available With over 95% of the over 7,000 estimated rare diseases having no treatment, these products typically have no competition and thus no competitive data. This, in turn, calls for a more expert and specialized sales force.

Sales 52
article thumbnail

Why Sales Representatives Should Deviate from Call Plans

The Marketing Advantage

July 10, 2023 One of the functions most critical to maximizing the productivity and efficiency of the sales force’s efforts is call planning —how often a physician target should be seen by a sales representative. In fact, in one case, the prescriber was the spouse of a competitive sales representative.

Sales 40
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Five IDNs to watch in 2023

Clarivate

In a fiercely competitive U.S. While marquee IDNs attract national headlines, these smaller systems reflect how markets are adjusting to an increasingly value-based and competitive landscape. ChristianaCare’s future expansion plans could escalate the competition between Highmark and UPMC. ChristianaCare, Wilmington, Delaware.

article thumbnail

Gene therapies transform rare disease treatment: hope for patients amidst regulatory, payer and developer challenges

Clarivate

With 11 gene therapies already approved payers are bracing for impact as Cortellis Competitive Intelligence data identifies another 30 in late-stage pipelines. However, because this is a genetic condition and there’s a definitive diagnosis, hopefully that means the process will be relatively straightforward for patients and physicians.”